Morphic Medical, Inc.
GIDYL
OTC PK
| 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.34% | -50.46% | 43.33% | 16.37% | 13.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.71% | -42.12% | -7.62% | 12.54% | 25.16% |
| Operating Income | 23.71% | 42.12% | 7.62% | -12.54% | -25.16% |
| Income Before Tax | 16.47% | 26.30% | -31.38% | 70.95% | -21.98% |
| Income Tax Expenses | -- | -30.77% | -- | -80.77% | -16.67% |
| Earnings from Continuing Operations | 16.61% | 26.32% | -31.56% | 70.98% | -21.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.61% | 26.32% | -31.56% | 70.98% | -21.88% |
| EBIT | 23.71% | 42.12% | 7.62% | -12.54% | -25.16% |
| EBITDA | 24.12% | 42.17% | 7.64% | -12.68% | -23.68% |
| EPS Basic | -- | 100.00% | -- | 100.00% | -- |
| Normalized Basic EPS | 70.00% | 90.63% | 54.55% | 84.38% | 33.33% |
| EPS Diluted | -- | 100.00% | -- | 100.00% | -- |
| Normalized Diluted EPS | 70.00% | 90.63% | 54.55% | 84.38% | 33.33% |
| Average Basic Shares Outstanding | 140.71% | 800.91% | 135.02% | 89.85% | 89.85% |
| Average Diluted Shares Outstanding | 140.71% | 800.91% | 135.02% | 89.85% | 89.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
